{"groups":[{"description":"During the 12-week treatment period, participants receive a total of 5 subcutaneously (SC) doses of PF-06946860 every 3 weeks (Q3W).","id":"FG000","title":"PF-06946860 Q3W"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Global deterioration of health status"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Enrolled and not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 20 participants were screened for eligibility, of which 11 participants were enrolled into the study. A total of 10 participants were treated."}